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To the Editor, 
Patients with Autoimmune Polyendocrine Syndrome Type 1 (APS-1) provide a fascinating setting to 
study the association of human neutralizing autoantibodies against cytokines and allergy symptoms. 
This rare monogenic autosomal recessive disease, caused by mutations in the autoimmune 
regulator (AIRE) gene, classically presents with chronic mucocutaneous candidiasis and endocrine 
organ-specific autoimmunity. Typical features include accumulation of autoreactive T-cells and the 
presence of notable levels of high-affinity neutralizing autoantibodies, not only against tissue 
antigens but also against cytokines. Interestingly, some of the APS anti-cytokine autoantibodies 
have been claimed to be disease ameliorating [1] and could therefore contribute to the lack of 
reported classical asthma and allergy symptoms among APS-1 patients. 
To advance our understanding on the role of human anti-cytokine antibodies on asthma or allergy, 
we enrolled 10 male and 19 female Finnish APS-1 patients and investigated the relationship 
between IgE sensitization, asthma and allergy symptoms and circulating cytokine autoantibodies 
(Figure 1).  Our APS-1 patients had a mean age of 46 years, all encompassed the same Finn major 
AIRE mutation genotype and and all but one had been diagnosed with chronic mucocutaneous 
candidiasis (CMC), as part of the classic diagnostic triad of APS-1 symptoms. The full clinical outline 
of our cohort is available in our previous publication [2]. 
IgE sensitization to the 112 most common allergen components was tested using ImmunoCAP 
immuno-solid phase allergen chip (ISAC) sIgE-microchip. Four of the 29 (14%) APS-1 patients none 
of which with asthma, were detected to be sensitized to one or more IgE chip allergen using a 
threshold of 0.3 ISAC standard unit. The positive results were for birch pollen (and cross-reactive 
PR-10 allergen components), common wasp, timothy and for domestic cat. One patient was triple 










allergen: common wasp (one patient) or birch pollen (two patients). The relatively low rate of atopy 
is consistent with local prevalence of allergic rhinoconjunctivitis and asthma in Finnish middle-aged 
patients [3]. 
For allergy and asthma symptoms, peak expiratory flow (PEF), spirometry measurements and skin 
prick test results were inquired and information on the use of asthma medication and allergy 
symptoms (excluding drug allergies and atopic dermatitis) were collected with a structured 
questionnaire.  Out of the 29 patients participating our study, four female patients (14%) had a 
diagnosed asthma (Figure 1). They all had been prescribed inhalant corticosteroids and 
sympaticomimetics and two of them used inhalants regularly. Of note, pulmonary autoimmunity 
has not been observed in this patient cohort during treatment and regular check-ups at university 
hospital level [2]. Regarding other allergy symptoms, 14 of the 29 patients reported symptoms.  
Eight patients reported conjunctival or nasal symptoms from birch pollen, three of them were 
validated by the IgE chip. Six patients reported symptoms from cat, but only one of these was 
validated by the IgE chip. Upper respiratory track symptoms from various fruit, nuts, fish and mold 
were also recorded, but no IgE sensitization data agreed with this information, reflecting low general 
specificity of self-reported symptoms. Notably, chronic mucocutaneous Candida infection may 
mimic food allergy symptoms. The one patient without history of CMC did not report allergy 
symptoms, nor tested positive on the IgE chip nor had asthma.  
Serum autoantibodies against 81 cytokines and against three non-cytokine proteins (sclerostin, 
spartin and synphilin-1) were measured with enzyme-linked immunosorbent assay using 
recombinant antigens. Healthy sera from blood donors served as negative controls. Of the twelve 
inflammatory cytokines[4] and 17 chemokine ligands [4, 5] previously associated with asthma, our 










IL-4, IL-5, IL-6, IL-7, IL-13, IL-17A, IL-17F, IL-22, IL-23, IL-25 and CCL2, CCL3, CCL7, CCL11, CCL13, 
CCL17, CCL22, CCL24, CCL26 as well as CXCL1, CXCL5, CXCL9, CXCL10, CXCL11, CXCL12a, CXCL12b, 
CXCL13.  
All patients typically had autoantibodies at an optical density (OD) level of 0.04 against several 
cytokines: all had autoantibodies against IFNα1b and IFNα5. The majority (28/29) of patients had 
autoantibodies against IFNα2b, IL-22 and IFNα4, while 25/29 patients had autoantibodies against 
IL-17F. In relation to the rest of the above mentioned asthma-associated chemokines, CCL13- and 
CXCL12a-specific autoantibodies were detected in one patient each. None of the patients had 
autoantibodies against IL-1β, IL3, IL-6, IL-13, IL-23, IL-25, CCL3, CCL7, CCL17, CCL24, CCL26, CXCL1, 
CXCL5, CXCL9 and CXCL12b. The potent neutralizing capacity of the above anti-cytokine 
autoantibodies has been previously reported [1].  
Associations between clinical, symptom and assay variables were examined by means of T -tests 
followed by Benjamin-Hochberg false discovery rate multiple testing correction. Significance was 
defined using thresholds of 0.05 and 0.20 (Figure 2). Hierarchical clustering (Euclidean distance and 
Wards-linkage) was used to visualize data. These analyses revealed the distinct presence of three 
anti-cytokine antibodies IL-17F, IL-11 and IFN-ω1 between asthmatic and non-asthmatic patients 
(Figure 3). In particular, asthmatic APS-1 patients had a lower mean IL-17F antibody level compared 
to the non-asthmatic APS-1 patients (optical density 0.53 +/- 0.43 vs. 2.11 +/- 1.02, Q<0.05; Figure 
3) suggesting that anti-IL-17F autoantibodies may provide protection against asthma.  
The IL-17F pathway has a central role in the pathogenesis of asthma. It is involved in airway hyper 
reactivity, neutrophil infiltration, mucus hypersecretion and goblet cell hyperplasia, subepithelial 
fibrosis and smooth muscle cell hyperplasia as well as steroid resistance in asthmatic lung tissue [6]. 










bronchial neutrophils, poorer lung function and more frequent exacerbation rates in asthmatics [7]. 
In murine models, blocking IL-17 has in turn been shown to ameliorate asthma phenotype. For 
example, the blockage of either IL-17F or IL-17A by both neutralizing antibodies or deficiency of the 
cytokine has been shown to prevent house dust mite -induced allergic asthma in mice [8]. Mice 
genetically lacking IL-17F have been noted to be more resistant to allergic bronchopulmonary 
aspergillosis upon intranasal challenge compared to wild type, and treatment with neutralizing IL-
17Fab has been shown to reduce signs of respiratory allergy and lung inflammation in wild type mice 
[9]. In a Japanese case control study, a loss-of-function IL-17F mutation negatively correlates with 
asthma/COPD [10]. Moreover, a therapeutic anti-IL-17A monoclonal antibody is the subject of an 
ongoing clinical trial with severe asthmatics and a new trivalent monomeric neutralizing IL-17A/F 
Nanobody is studied for the treatment of psoriasis (clinicaltrials.gov) but no IL-17F targeting 
monoclonal antibody has yet been brought to clinical trials for treatment of asthma.   
In conclusion, this study suggests a disease ameliorating role for IL-17Fab and indicates that IL-17F 
autoantibodies may provide protection against asthma, despite the limited sample size due to the 
rarity of APS-1. In future prospective studies, IL-17F levels could be verified using a larger study 
cohort as well as in bronchoalveolar lavage sampling. All in all, this study underlines the importance 
of  disease ameliorating properties of APS-1 anti-cytokine autoantibodies. 
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Figure 1. The study design. The study included altogether 19 female and 10 male APS-1 patients.  
All of the enrolled 29 APS-1 patients donated blood samples that were tested for autoantibodies 
against 81 cytokines as well as for 112 allergen-specific IgE antibodies with the ImmunoCAP ISAC 
sIgE-microchip. All 29 APS-1 patients also filled out a structured questionnaire about allergy and 
asthma symptoms.      
 
Figure 2. Analysis of serum cytokine autoantibody data in relation to allergy and asthma 
symptoms and findings.   
Hierarchical clustering analysis of serum autoantibody data. Cytokines against which none of the 
patients had autoantibodies were filtered prior to statistical testing. Top left column bar shows 
various patient classification variables for each patient marked with black and grey colors. Dark grey 
stands for missing information on one patient. Lower left corner highlights statistically significant 
differences of autoantibody values (FDR<0.2 marked in grey and <0,05 marked in black) between 
patients with or without IgE-mediated allergic sensitization, allergy symptoms, asthma, allergy or 
asthma medication, prick and/or PEF/spirometry tests performed, time point of symptom onset in 
childhood or adulthood, and between asthma and nonasthmatic/nonsensitized, and IgE-sensitized 
and nonasthmatic/nonsensitized patients. 
Association between IL17F and asthma is shown on lines 3 and 12 (FDR<0.2 marked in grey and 
<0,05 marked in black).  
 
Figure 3. Box-plots of statistically significant serum cytokine autoantibodies between APS-1 
patients without and with asthma. Serum anticytokine autoantibody OD signal intensity box plot 























 14/29 (48%) APS-1 patients had allergy symptoms, only 4 (14%) verified by IgE chip 
 4/29 (14%) APS-1 patients had asthma 
 The presence of anti-IL17F autoantibodies is associated with lack of asthma symptoms 
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